amit@unlistedkraft.in
+91-9599071664
+91-9599071664
Veeda Clinical Research
DRHP Status : Not Filed
499
Current Price
499
Market Cap
3370 Cr
ISIN
INE01HQ01026
Face Value
10
P/E Ratio
-9158.9
EPS
-0.06
P/B Ratio
3.2
Book Value
169
Debt to Equity Ratio
0.25
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 196 | 288 | 409 | 388 |
| Cost of Material Consumed | 14 | 28 | 33 | 38 |
| Gross Margins | 92.86 | 90.28 | 91.93 | 90.21 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Employee Benefit Expenses | 49 | 87 | 109 | 126 |
| Other Expenses | 66 | 111 | 164 | 171 |
| EBITDA | 67 | 62 | 103 | 53 |
| OPM | 34.18 | 21.53 | 25.18 | 13.66 |
| Other Income | 38 | 39 | 8 | 19 |
| Finance Cost | 5 | 10 | 14 | 14 |
| D&A | 15 | 25 | 38 | 53 |
| EBIT | 52 | 37 | 65 | 0 |
| EBIT Margins | 26.53 | 12.85 | 15.89 | 0 |
| PBT | 85 | 65 | 59 | 3.3 |
| PBT Margins | 43.37 | 22.57 | 14.43 | 0.85 |
| Tax | 22 | 15 | 17 | 3.6 |
| PAT | 63 | 50 | 42 | -0.3 |
| NPM | 32.14 | 17.36 | 10.27 | -0.08 |
| EPS | 17.6 | 9.46 | 8 | -0.04 |
Financial Ratios |
2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | 34.18 | 21.53 | 25.18 | 13.66 |
| Net Profit Margin | 32.14 | 17.36 | 10.27 | -0.08 |
| Earning Per Share (Diluted) | 17.6 | 9.46 | 8 | -0.04 |
| Assets | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Fixed Assets | 38 | 185 | 236 | 190 |
| CWIP | 1 | 20 | 22 | 33 |
| Investments | 66 | 88 | 55 | 80 |
| Trade Receivables | 45 | 98 | 105 | 120 |
| Inventory | 6 | 8 | 7 | 7.2 |
| Other Assets | 129 | 278 | 310 | 1610 |
| Total Assets | 285 | 677 | 735 | 2040.2 |
| Liabilities | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Share Capital | 35.8 | 10.57 | 10.5 | 13.599 |
| FV | 10 | 2 | 2 | 2 |
| Reserves | 134 | 426 | 452 | 1047 |
| Borrowings | 24 | 47 | 48 | 260 |
| Trade Payables | 12 | 25 | 22 | 247 |
| Other Liabilities | 79.2 | 168.43 | 202.5 | 473 |
| Total Liabilities | 285 | 677 | 735 | 2040.6 |
| Name | Holding |
|---|---|
| Basil Private Limited | 35.42% |
| Bondway Investment Inc | 20.45% |
| Sabre Partners AIF Trust | 4.8% |
| Others | 39.65% |
About Company
Veeda Clinical Research is a full-service Contract Research Organization (CRO) offering comprehensive drug development solutions from preclinical to late-stage development.
They have a global presence with facilities in India (Ahmedabad and Bangalore) and a growing footprint in North America and Europe. Veeda specializes in early and late-phase clinical trials, healthy volunteer studies, pre-clinical trials, and biopharma services.
They are known for their strong compliance culture, regulatory approvals, and focus on technology-driven solutions.
Click here to visit the official website of Veeda Clinical Research.
FAQs
Veeda Clinical Research Ltd unlisted shares represent equity in a private contract research organisation (CRO) based in Gujarat, offering full-service clinical and preclinical drug development support. These shares are not listed on NSE or BSE and can be acquired through platforms like UnlistedKraft.
Yes, UnlistedKraft provides verified access to Veeda Clinical Research Ltd unlisted shares. After completing your KYC and placing your order, the shares are typically credited to your demat account within 24 hours.
Unlisted investments carry risks like limited liquidity and reduced transparency. However, Veeda is a reputed CRO with global client partnerships and is backed by institutional investors. UnlistedKraft ensures secure and verified transactions to safeguard investor interests.
Pricing is based on recent private transactions, investor demand, the company’s financial position, and IPO expectations. UnlistedKraft regularly updates share prices to reflect fair and current valuation.
Yes, a valid demat account is required to receive and hold unlisted shares of Veeda Clinical Research Ltd.
There is no mandatory lock-in period unless the company is listed publicly. Investors generally hold these shares until a liquidity event such as an IPO or institutional exit to maximise potential returns.
Yes, you can sell your shares via UnlistedKraft’s resale network, subject to buyer interest and prevailing secondary market demand.
Yes, as per SEBI regulations, any shares purchased before listing are subject to a six-month lock-in period post-IPO.
If shares are held for more than two years, long-term capital gains are taxed at 20% with indexation. Gains from shares sold within two years are treated as short-term and taxed as per your income tax slab.
UnlistedKraft offers reliable access to unlisted equity of companies like Veeda Clinical Research Ltd, with transparent pricing, expert support, secure transaction processing, and quick credit of shares to your demat account, ensuring a seamless and trustworthy investment experience.
+91-9599071664
amit@unlistedkraft.in